Biogen Canada was established in Mississauga, Ontario in April 1998 and has been conducting business in Canada for more than 15 years. The scope of our operations has continued to expand and has helped to improve the care of individuals affected by multiple sclerosis (MS) and spinal muscular atrophy (SMA).
In Canada, Biogen contributes to the life science sector through its investments in research and development.
There are currently 8 therapy areas where Biogen is doing research in Canada, including: MS, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), large hemispheric infarction, Parkinson’s Disease, progressive supranuclear palsy, SMA and pain.
Biogen Canada provides important support services to patients in Canada:
- Our Biogen ONE Support Program provides patients with a wide range of services, including patient education, injection training/infusion services, reimbursement and financial assistance support, and monitoring and side effect management.
- More than 60 people (including nurses and reimbursement support specialists) support more than 12,000 patients currently enrolled across Canada.
- SMA 360◦™ is the program supported by Biogen that provides SMA patients and their families with services, including financial assistance.
Biogen Canada provides competitive salaries, comprehensive benefits and flexible working conditions.